Interaction between the LMWH reviparin and aspirin in healthy volunteers

• Published in: British journal of clinical pharmacology Vol. 49; no. 4; pp. 337 - 341
• Main Authors: Klinkhardt, Ute, Breddin, Hans Klaus, Esslinger, Heinz Ulrich, Haas, Silvia, Kalatzis, Andreas, Harder, Sebastian
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.04.2000; Blackwell Science; Blackwell Science Inc
• Subjects: Adult; Anticoagulants - adverse effects; Anticoagulants - pharmacology; ASA‐interaction; Aspirin - adverse effects; Aspirin - pharmacology; Biological and medical sciences; Bleeding Time; Blood. Blood coagulation. Reticuloendothelial system; Cross-Over Studies; Double-Blind Method; Drug Interactions; Factor Xa - metabolism; Female; Hemostasis - drug effects; Heparin, Low-Molecular-Weight - adverse effects; Heparin, Low-Molecular-Weight - pharmacology; Humans; Male; Medical sciences; Partial Thromboplastin Time; Pharmacology. Drug treatments; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Function Tests; reviparin; Human; Reviparin sodium; Blood coagulation; Drug combination; Healthy subject; Low molecular weight heparin; Anticoagulant; Acetylsalicylic acid; Bleeding time; Antiplatelet agent; Aggregation; Platelet; Hemostasis; Partial thromboplastin time; Drug interaction; Heparin; Salicylates
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1046/j.1365-2125.2000.00173.x

Aims To investigate potential interactions between reviparin and acetylsalicylic acid (ASA 300 mg o.d. from day 1–5). Methods In an open, randomized, three‐way‐cross over study nine healthy volunteers received reviparin (s.c. injection of 6300 anti‐Xa units) or placebo from days 3 to 5 and acetylsalicylic acid (ASA 300 mg) or placebo from days 1 to 5. Assessments included bleeding time (BT), collagen (1 µg ml−1) induced platelet aggregation (CAG), heptest, plasma antifactor Xa‐activity and activated partial thromboplastin time (aPTT). Results Median bleeding time at day 5 was 5.5 min after reverparin alone and after ASA alone and was 9.6 min after the combination of reviparin and ASA. ASA treatment reduced CAG from 84% to 40 to 50% of Amax; values after combined treatment of reviparin with ASA were not different from those after ASA alone. aPTT was prolonged to 32 s after reviparin; this effect was not modified if subjects received ASA. Combined treatment with ASA and reviparin had no effect on plasma anti‐Xa‐activity and heptest compared with reviparin alone. Conclusions We could not entirely exclude a small interaction between reviparin and ASA on bleeding time, but the effect is probably without clinical significance.